Royalty Pharma Analyst Ratings
Royalty Pharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/11/2023 | 100.93% | Morgan Stanley | $53 → $54 | Maintains | Overweight |
| 08/09/2023 | 97.21% | Morgan Stanley | $52 → $53 | Maintains | Overweight |
| 07/11/2023 | 93.49% | Morgan Stanley | $52 → $52 | Reiterates | Overweight → Overweight |
| 05/10/2023 | 93.49% | Morgan Stanley | $50 → $52 | Maintains | Overweight |
| 04/10/2023 | 86.05% | Morgan Stanley | $48 → $50 | Maintains | Overweight |
| 04/06/2023 | 123.26% | Tigress Financial | $57 → $60 | Reiterates | → Buy |
| 02/16/2023 | 78.6% | UBS | $51 → $48 | Maintains | Buy |
| 12/06/2022 | 89.77% | Morgan Stanley | $54 → $51 | Maintains | Overweight |
| 11/09/2022 | 100.93% | Morgan Stanley | $51 → $54 | Maintains | Overweight |
| 10/18/2022 | 93.49% | JP Morgan | $50 → $52 | Maintains | Overweight |
| 08/08/2022 | 89.77% | Morgan Stanley | $48 → $51 | Maintains | Overweight |
| 07/14/2022 | 112.09% | Tigress Financial | $52 → $57 | Maintains | Buy |
| 06/14/2022 | 74.88% | UBS | → $47 | Initiates Coverage On | → Buy |
| 05/13/2022 | 97.21% | Scotiabank | → $53 | Initiates Coverage On | → Outperform |
| 04/27/2022 | 108.37% | Goldman Sachs | → $56 | Initiates Coverage On | → Buy |
| 04/14/2022 | 86.05% | JP Morgan | → $50 | Upgrades | Neutral → Overweight |
| 04/06/2022 | 78.6% | Morgan Stanley | $46 → $48 | Upgrades | Equal-Weight → Overweight |
| 10/29/2021 | 86.05% | Citigroup | → $50 | Upgrades | Neutral → Buy |
| 08/16/2021 | 71.16% | Morgan Stanley | $51 → $46 | Maintains | Equal-Weight |
| 07/30/2021 | 86.05% | Tigress Financial | → $50 | Initiates Coverage On | → Buy |
| 11/09/2020 | 89.77% | UBS | → $51 | Upgrades | Neutral → Buy |
| 07/13/2020 | 86.05% | JP Morgan | → $50 | Initiates Coverage On | → Neutral |
| 07/13/2020 | 104.65% | B of A Securities | → $55 | Initiates Coverage On | → Buy |
| 07/13/2020 | 89.77% | Morgan Stanley | → $51 | Initiates Coverage On | → Equal-Weight |
| 07/13/2020 | 104.65% | Cowen & Co. | → $55 | Initiates Coverage On | → Outperform |
| 07/13/2020 | 108.37% | SunTrust Robinson Humphrey | → $56 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 2023年10月11日 | 100.93% | 摩根士丹利 | $53→$54 | 维护 | 超重 |
| 08/09/2023 | 97.21% | 摩根士丹利 | $52→$53 | 维护 | 超重 |
| 07/11/2023 | 93.49% | 摩根士丹利 | $52→$52 | 重申 | 超重→超重 |
| 2023年05月10日 | 93.49% | 摩根士丹利 | $50→$52 | 维护 | 超重 |
| 04/10/2023 | 86.05% | 摩根士丹利 | $48→$50 | 维护 | 超重 |
| 04/06/2023 | 123.26% | 虎妞金融 | $57→$60 | 重申 | →购买 |
| 02/16/2023 | 78.6% | 瑞银集团 | $51→$48 | 维护 | 买 |
| 12/06/2022 | 89.77% | 摩根士丹利 | $54→$51 | 维护 | 超重 |
| 11/09/2022 | 100.93% | 摩根士丹利 | $51→$54 | 维护 | 超重 |
| 10/18/2022 | 93.49% | 摩根大通 | $50→$52 | 维护 | 超重 |
| 2022/08/08 | 89.77% | 摩根士丹利 | $48→$51 | 维护 | 超重 |
| 07/14/2022 | 112.09% | 虎妞金融 | $52→$57 | 维护 | 买 |
| 2022/06/14 | 74.88% | 瑞银集团 | →$47 | 开始承保 | →购买 |
| 2022年05月13日 | 97.21% | 加拿大丰业银行 | →$53 | 开始承保 | →跑赢大盘 |
| 04/27/2022 | 108.37% | 高盛 | →$56 | 开始承保 | →购买 |
| 04/14/2022 | 86.05% | 摩根大通 | →$50 | 升级 | 中性→超重 |
| 04/06/2022 | 78.6% | 摩根士丹利 | $46→$48 | 升级 | 等重→超重 |
| 10/29/2021 | 86.05% | 花旗集团 | →$50 | 升级 | 中性→购买 |
| 08/16/2021 | 71.16% | 摩根士丹利 | $51→$46 | 维护 | 等重 |
| 07/30/2021 | 86.05% | 虎妞金融 | →$50 | 开始承保 | →购买 |
| 11/09/2020 | 89.77% | 瑞银集团 | →$51 | 升级 | 中性→购买 |
| 07/13/2020 | 86.05% | 摩根大通 | →$50 | 开始承保 | →中性 |
| 07/13/2020 | 104.65% | B of A证券 | →$55 | 开始承保 | →购买 |
| 07/13/2020 | 89.77% | 摩根士丹利 | →$51 | 开始承保 | →等重 |
| 07/13/2020 | 104.65% | 考恩公司 | →$55 | 开始承保 | →跑赢大盘 |
| 07/13/2020 | 108.37% | SunTrust Robinson Humphrey | →$56 | 开始承保 | →购买 |
What is the target price for Royalty Pharma (RPRX)?
Royalty Pharma(RPRX)的目标价是多少？
The latest price target for Royalty Pharma (NASDAQ: RPRX) was reported by Morgan Stanley on October 11, 2023. The analyst firm set a price target for $54.00 expecting RPRX to rise to within 12 months (a possible 100.93% upside). 10 analyst firms have reported ratings in the last year.
版税医药(纳斯达克：RPRX)的最新目标价是由摩根士丹利于2023年10月11日报道的。这家分析公司将目标价定为54美元，预计RPRX将在12个月内升至(可能上涨100.93%)。去年有10家分析公司公布了评级。
What is the most recent analyst rating for Royalty Pharma (RPRX)?
Royalty Pharma(RPRX)的最新分析师评级是多少？
The latest analyst rating for Royalty Pharma (NASDAQ: RPRX) was provided by Morgan Stanley, and Royalty Pharma maintained their overweight rating.
王者医药(纳斯达克股票代码：RPRX)的最新分析师评级由摩根士丹利提供，皇室医药维持增持评级。
When is the next analyst rating going to be posted or updated for Royalty Pharma (RPRX)?
Royalty Pharma(RPRX)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Royalty Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Royalty Pharma was filed on October 11, 2023 so you should expect the next rating to be made available sometime around October 11, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与Royalty Pharma的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Royalty Pharma的上一次评级是在2023年10月11日提交的，因此您应该预计下一次评级将在2024年10月11日左右提供。
Is the Analyst Rating Royalty Pharma (RPRX) correct?
分析师对Royalty Pharma(RPRX)的评级正确吗？
While ratings are subjective and will change, the latest Royalty Pharma (RPRX) rating was a maintained with a price target of $53.00 to $54.00. The current price Royalty Pharma (RPRX) is trading at is $26.88, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Royalty Pharma(RPRX)评级维持不变，目标价在53.00美元至54.00美元之间。Royalty Pharma目前的交易价格为26.88美元，超出了分析师的预测区间。
译文内容由第三方软件翻译。